Tech Company Financing Transactions
Rgenta Therapeutics Funding Round
On 11/29/2022, Rgenta Therapeutics raised $52 million in Series A funding from AstraZeneca, Delos Capital and Korea Investment Partners.
Transaction Overview
Company Name
Announced On
11/29/2022
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series A
Investors
Proceeds Purpose
The company plans to use the funding to speed up the development of the lead programs, enhance target discovery, extend platform capabilities, and advance a pipeline of RNA-targeting programs against a range of disease indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St. LabCentral
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Simon Xi
Chief Scientific Officer
Travis Wager
Browse more venture capital transactions:
Prev: 11/29/2022: Saltbox venture capital transaction
Next: 11/29/2022: Range Energy venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs